nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-D3901E7E·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Psychiatry and Mental health·Basis: Full text·Type: Observational cohort study

Prevalence of high-risk plasma p-tau217 levels and 5-year transition of risk status in 70-year-olds.

Dittrich et al.Dittrich, Arslan, Skillbäck et al.·2026·Alzheimer's & dementia : the journal of the Alzheimer's Association·10.1002/alz.71545 ↗

Primary claim

High-risk plasma p-tau217 prevalence was 3.6% at age 70 and 7.0% at age 75-77 years.

Tentative · the follow-up percentage is based on a retained cohort after substantial differential attrition
In brief

A useful community cohort maps p-tau217 risk transitions over five years, but differential attrition limits the follow-up prevalence and prognostic interpretation.

ReliabilityCaveats4 of 4 checks completeRead the entry ↓
Fragile — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

INTRODUCTION: High-risk plasma p-tau217 levels predict amyloid-β pathology in Alzheimer's disease, but little is known about the prevalence and temporal dynamics in the general population.

METHODS: Participants from the Gothenburg H70 Birth Cohort Study in Sweden were examined (n = 1157) and re-examined after 5-7 years (n = 771). Prevalence and 5-7 year transition of high-risk plasma p-tau217 status was determined among community-dwelling 70-year-olds.

RESULTS: High-risk plasma p-tau217 prevalence was 3.6% at age 70 and 7.0% at age 75-77 years. Eighty-nine percent remained low-risk and 4% converted to high-risk at follow-up. Prevalence of dementia at follow-up was 1.7% if remaining in the low-risk group and 21.4% if transitioning to the high-risk group. Prevalence of dementia among participants staying in the high-risk group was 16.7% at follow-up.

DISCUSSION: Individuals with low-risk plasma p-tau217 were unlikely to transition over 5-7 years. However, transitioning to a higher risk-category was associated with a higher prevalence of cognitive disability.

Key Claims

Primary finding · Tentative

High-risk plasma p-tau217 prevalence was 3.6% at age 70 and 7.0% at age 75-77 years.

Fragile — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

the follow-up percentage is based on a retained cohort after substantial differential attrition

Abstract; Results, Prevalence of high-risk plasma p-tau217
Quote verified
Secondary · Supported

Individuals with low-risk plasma p-tau217 were unlikely to transition over 5-7 years.

the repeated cohort shows 89% remained low-risk, although attrition limits population-level inference

Abstract, Discussion
Quote verified
Secondary · Supported

Prevalence of dementia at follow-up was 1.7% if remaining in the low-risk group and 21.4% if transitioning to the high-risk group.

the reported contrast is direct but rests on a small transition group without precision estimates

Abstract; Results, Cognitive outcomes at follow-up
Quote verified
Secondary · Tentative

Individuals who transitioned to a higher risk-category over time also had a higher prevalence of cognitive disability at follow-up, demonstrating increased risk for future cognitive decline among community-dwelling 70-year-olds.

concurrent follow-up measurements support association but do not establish subsequent future decline

Discussion, Conclusion
Quote verified
Secondary · Tentative

The increase in plasma p-tau217 concentrations was higher among individuals who increased in CDR.

one supporting progression comparison contains an impossible median and interquartile range

Results, Characteristics of participants stratified by plasma p-tau217 at baseline and follow-up
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Longitudinal community biomarker measurements

The study measures plasma p-tau217 in 1,157 participants at baseline and in 771 participants at both waves, addressing a documented gap in repeated community-based estimates.

↳ Methods, Design and Participants; Research in Context

#methodological rigour

Transparent follow-up accounting

Loss to follow-up is reported by baseline risk category, including the markedly higher loss from the high-risk group. This makes the principal selection limitation visible to readers.

↳ Results, Loss to follow-up

#methodological rigour

Cutoff uncertainty directly examined

The analysis tests whether transitioners cluster in the uncertain regions around the cutoffs and reports no clear overall pattern, directly addressing one possible source of category instability.

↳ Results, The influence of confidence intervals for rate of transition; Figure S1

Limitations

#methodological rigour

Impossible reported median and IQR

For participants progressing from CDR 0.5, the reported median change of 0.25 pg/mL lies below the IQR lower bound of 0.28 pg/mL. The affected progression comparison cannot be accepted as printed.

↳ Results, Characteristics of participants stratified by plasma p-tau217 at baseline and follow-up

#methodological rigour

Differential attrition remains uncorrected

Loss reached 67% among baseline high-risk participants versus 32% among low-risk participants, yet no weighting or missing-data sensitivity analysis is reported. The 7.0% follow-up estimate therefore describes the retained sample rather than a securely estimated population prevalence.

↳ Results, Loss to follow-up; Discussion, Limitations

#reporting

Prospective conclusion exceeds design

Transition status and cognitive status are assessed at the same follow-up visit, but the conclusion says this demonstrates future cognitive decline. The evidence supports a concurrent association, not that prospective inference.

↳ Discussion, Conclusion

Does this match your read? Add your assessment ↓

Nabu Commentary

The representative community sampling and repeated p-tau217 measurements provide a useful longitudinal description of risk-category dynamics. Methodological Rigour is limited by differential attrition, especially the 67% loss from the baseline high-risk group, without a quantitative missing-data analysis. The conclusion also treats cognitive status measured alongside transition status as evidence of future decline. Most importantly, the CDR 0.5 progression result reports a median outside its stated interquartile range and requires correction before that comparison can be relied upon.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.4±0.2

Contribution
3.7

The study adds age-specific, repeated community measurements of p-tau217 risk status and associated cognitive outcomes. Its advance is meaningful but descriptive, with small intermediate- and high-risk groups.

Research in Context; Methods, Design and Participants; Results, Transitions between risk groups

studies reporting age-specific prevalence of pathological levels, and repeated measurements of plasma-p-tau217...were missing

Methodological Rigour
3.2

The population sampling, repeated assay measurements, prespecified cutoffs, and cutoff-uncertainty analysis fit the descriptive aims. Differential attrition is substantial and receives no weighting or sensitivity analysis, while one CDR-change statistic is internally impossible.

Methods, Participants and Lumipulse plasma p-tau217; Results, Loss to follow-up; Results, CDR-change analysis

In the high-risk group 28 (67%) participants were lost to follow-up

Reporting
3.4

The manuscript presents its cohort, transition counts, and cognitive comparisons in a generally followable sequence. The conclusion nevertheless converts concurrent transition and follow-up cognitive status into a claim about future decline.

Abstract; Results, Cognitive outcomes at follow-up; Discussion, Conclusion

demonstrating increased risk for future cognitive decline

Positioning
3.5

The Discussion compares the observed prevalence with CSF and amyloid-PET estimates and acknowledges attrition, ancestry, and small subgroups. Contextual treatment is incomplete for renal influences on plasma p-tau217 and analytical variability near the decision cutoffs.

Discussion, paragraphs 2 and 5; Discussion, Limitations

The potential influence of these lost participants should be considered when interpreting this study

Reliability

Caveats4 of 4 checks


Results checkNoted
  • The increase in plasma p-tau217 concentrations was higher among individuals who increased in CDR: "Similarly, increases in plasma p‐tau217 were higher in individuals who increased from CDR 0.5 at baseline to a higher CDR at follow‐up (0.02 [0.00–0.04] pg/mL and 0.25 [0.28–0.45] pg/mL respectively, median [IQR], p‐value = 0.001)." (Results, Characteristics of participants stratified by plasma p-tau217 at baseline and follow-up). The reported median of 0.25 pg/mL is below the first quartile of 0.28 pg/mL, violating the required ordering Q1 ≤ median ≤ Q3. → Effect on result unclear
Reporting and transparencyClean

No supplied concern establishes a reporting or research-conduct finding.

Conflict of interest: declared · Ethics approval: declared

Reference IntegrityClean

32 references in manuscript 32 of 32 checkable references found in an index

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceEmpirical
Route to useNamed
AdvanceExtends
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

Findings come from a single longitudinal population cohort in Gothenburg with no independent replication of prevalence or transition rates in another setting.

From the paper
“This should be considered when clinically determining the frequency of re-testing low-risk individuals with plasma-p-tau217”

The paper names a clinical setting where clinicians would use these findings to decide re-testing frequency and further cognitive assessment of transitioners.

Pathway

Clinicians in primary care and memory clinics could use population p-tau217 risk data to time re-testing and select older adults for further cognitive assessment.

Barrier

Evidence rests on one Swedish cohort with substantial high-risk loss to follow-up, and no demonstration that screening asymptomatic older adults changes clinical outcomes.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals

    2026 · Clinical medicine

    Primary claim

    decreased ACD was associated with greater AD pathological burden

    Supported
    Evidence Score
    3.2±0.2
    Reliability
    Caveats
  2. The potential of low-field MRI for global dementia care

    2026 · Clinical medicine

    Primary claim

    Studies demonstrate reliable detection of core Alzheimer disease markers, including hippocampal atrophy and white matter hyperintensities, on portable low-field systems, with promising correspondence to conventional high-field MRI findings.

    Tentative
    Evidence Score
    3.7±0.1
    Reliability
    Caveats
  3. UK Biobank at 20 - a growing, global resource for dementia research

    2026 · Clinical medicine

    Evidence Score
    3.2±0.2
    Reliability
    Caveats

How the rubric works →